Article Sidebar

PDF
Date Published: 13/03/2022
Abstract Views: 209
Views PDF: 165
DOI: https://doi.org/10.51298/vmj.v510i2.1956
Issue
Vol. 510 No. 2 (2022)
Section
Các bài báo
How to Cite
Bùi Quý Quyền, Đào ., Việt Hoà, T. ., & Trung Vinh, H. . (2022). RELATIONSHIP BETWEEN BONE DENSITIES AND SOME CLINICAL AND SUBCLINICAL FEATURES IN PATIENTS WITH LUPUS NEPHRITIS. Vietnam Medical Journal, 510(2). https://doi.org/10.51298/vmj.v510i2.1956

RELATIONSHIP BETWEEN BONE DENSITIES AND SOME CLINICAL AND SUBCLINICAL FEATURES IN PATIENTS WITH LUPUS NEPHRITIS

Đào Bùi Quý Quyền1,, Trầm Việt Hoà2, Hoàng Trung Vinh3
1 Cho Ray Hospital
2 Bao Anh Clinic, Trang Bom district, Dong Nai province
3 Military Hospital 103, Vietnam Military Medical University

Main Article Content

Abstract

Objectives: Investigate the relationship between bone density and some clinical and subclinical characteristics in patients with systemic lupus erythematosus who have been receiving long-term corticosteroid therapy. Subjects and methods: Cross-sectional study of 83 patients diagnosed with lupus nephritis. All patients were measured bone density by DEXA method. Results: The mean age of patients with lupus nephritis was 28.13 ± 9.21, the rate of male was 13.3%, female accounted for 86.7%. The mean duration of steroid treatment was 39.44 ± 43.74 months. Bone density was significantly related with duration of steroid use and BMI. Bone density is negatively correlated, moderately with BMI and with the duration of use steroid, the correlation coefficient is -0.454, p<0.001. Bone density is not related to age, renal failure status in patients with lupus nephritis who use high-dose and long-term steroids. Conclusion: Decreased bone density associated with overweight and obesity, long-term steroid use in patients with lupus nephritis.

Article Details

Keywords

Lupus nephritis, bone Density, duration of use steroid, BMI

References

1. Lưu Ngọc Giang, Lê Anh Thư, Nguyễn Hải Thủy (2018).Nghiên cứu mật độ xương ở phụ nữ trên 45 tuổi thừa cân, béo phì. Tạp chí Y Dược Học, Trường Đại học Y Dược Huế, 8 (3): 107 -111.
2. Boone JB, Wheless L, Camai A, et al. (2021).Low prevalence of bone mineral density testing in patients with systemic lupus erythematosus and glucocorticoid exposure. Lupus. 30(3): 403–411.
3. Guo C, Fu R, Zhou M, et al. (2019). Pathogenesis of Lupus Nephritis: RIP3 Dependent Necroptosis and NLRP3 Inflammasome Activation. J Autoimmun. 103: 102286.
4. Li EK, Zhu TY, Hung VY, et al. (2010).Ibandronate increases cortical bone density in patients with systemic lupuserythematosus on long-term glucocorticoid. Arthritis Res Ther. 12(5): R198.
5. Palermo A, Tuccinardi D, Defeudis G, et al. (2016).BMI and BMD: The Potential Interplay between Obesity and Bone Fragility. Int J Environ Res Public Health. 13(6): 544.
6. Resende AL, dos Reis LM, Dias CB, et al. (2014).Bone Disease in Newly Diagnosed Lupus Nephritis Patients. PLoS One. 9(9): e106728.
7. Turcotte AF, O’Connor S, Morin SN, et al. (2021).Association between obesity and risk of fracture, bone mineral density and bone quality in adults: A systematic review and meta-analysis. PLoS One. 16(6): e0252487.